Global Panorama Blog

.Ovid Therapeutics actually revealed last month that it was trimming back its head count as the firm browses an unpredicted problem for the Takeda-partnered epilepsy

.Otsuka Drug has actually gotten Boston-based Jnana Therapeutics for $800 million so the Japanese biotech can get its palms on a clinical-stage oral phenylketonuria (PKU)

.Finnish biotech Orion has spied possible in Aitia’s “electronic twin” technician to build brand-new cancer drugs.” Digital twins” pertain to simulations that assist drug creators

.Cancer company Oncternal Rehabs is folding all its own professional tests and also laying off workers, turning its own electricity towards discovering tactical options including

.Eye medicine creator Ocuphire Pharma is actually obtaining genetics therapy developer Opus Genetic makeup in an all-stock transaction that will find the commercial-stage business adopt

.OS Therapies will certainly list on the NYSE American sell substitution today by means of a $6.4 thousand IPO that the biotech will certainly make

.After checking out at phase 1 data, Nuvation Bio has actually made a decision to halt service its one-time top BD2-selective BET inhibitor while considering

.Novo Nordisk is actually continuing its own push into genetic medicines, accepting to pay NanoVation Therapies approximately $600 thousand to work together on around seven

.Novo Nordisk has actually axed its own once-monthly twin GLP-1/ GIP receptor agonist, ending (PDF) advancement of a drug candidate that it singled out as

.Novo Nordisk has actually elevated the cover on a phase 1 test of its own dental amylin and also GLP-1 receptor co-agonist, connecting the prospect